Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William D Figg

Showing results (41-50 of 638) with videos related to

Pageof 64
Sort By:
Cell Cycle (Georgetown, Tex.)|December 5, 2009
New tricks from an old drug: a role for quinacrine in anti-cancer therapy?Cindy H Chau, William D Figg
The Lancet. Oncology|February 3, 2020
Stem cell clinics: risk of proliferationTristan M Sissung, William D Figg
Cancer Biology & Therapy|March 24, 2012
Angiogenesis inhibitors increase tumor stem cellsCindy H Chau, William D Figg
Cancer Biology & Therapy|April 19, 2017
A new predictive tool for postoperative radiotherapy in prostate cancerDaniel K Lee, William D Figg
The Oncologist|January 31, 2023
Evidence Regarding Pharmacogenetics in Pain Management and CancerD Max Smith, William D Figg
Cancer Biology & Therapy|July 16, 2004
Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogueMilin R Acharya, William D Figg
Cancer Biology & Therapy|March 2, 2005
Molecular and phenotypic heterogeneity of metastatic prostate cancerCindy H Chau, William D Figg
Cancer Biology & Therapy|April 1, 2006
ETS-TMPRSS2 fusion gene products in prostate cancerChristoph M Ahlers, William D Figg
Cancer Biology & Therapy|August 2, 2006
Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokineticsWilliam D Figg, Cindy H Chau
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2012
Aflibercept in pediatric solid tumors: moving beyond the trapCindy H Chau, William D Figg
Pageof 64

Showing results (41-50 of 638) with videos related to

Sort By:
Pageof 64
Cell Cycle (Georgetown, Tex.)|December 5, 2009
New tricks from an old drug: a role for quinacrine in anti-cancer therapy?Cindy H Chau, William D Figg
The Lancet. Oncology|February 3, 2020
Stem cell clinics: risk of proliferationTristan M Sissung, William D Figg
Cancer Biology & Therapy|March 24, 2012
Angiogenesis inhibitors increase tumor stem cellsCindy H Chau, William D Figg
Cancer Biology & Therapy|April 19, 2017
A new predictive tool for postoperative radiotherapy in prostate cancerDaniel K Lee, William D Figg
The Oncologist|January 31, 2023
Evidence Regarding Pharmacogenetics in Pain Management and CancerD Max Smith, William D Figg
Cancer Biology & Therapy|July 16, 2004
Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogueMilin R Acharya, William D Figg
Cancer Biology & Therapy|March 2, 2005
Molecular and phenotypic heterogeneity of metastatic prostate cancerCindy H Chau, William D Figg
Cancer Biology & Therapy|April 1, 2006
ETS-TMPRSS2 fusion gene products in prostate cancerChristoph M Ahlers, William D Figg
Cancer Biology & Therapy|August 2, 2006
Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokineticsWilliam D Figg, Cindy H Chau
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2012
Aflibercept in pediatric solid tumors: moving beyond the trapCindy H Chau, William D Figg
Pageof 64